List view / Grid view

Immunotherapy

 

Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application

10 December 2018 | By

This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.

Expert view: Multiplexed screens in biologics discovery

7 September 2018 | By

Biologics are the fastest growing class of therapeutics in the biopharmaceutical industry. A key driver for this growth is success with anti-cancer immunotherapeutics such as checkpoint modulation, adoptive cell therapy and bispecific T-cell engagers. While these approaches use different tactics to attack tumours, they often employ monoclonal antibodies to target…